Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada

Vaccine

Volumn 23, Issue 13, 2005, Pages 1549-1558

  Krahn, Murray D ^a,i   John Baptiste, Ava ^b   Yi, Qilong ^b   Doria, Andrea ^c   Remis, Robert S ^b   Ritvo, Paul ^b,d,e   Friedman, Samuel ^f,g,h  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d YORK UNIVERSITY   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f NATIONAL DEVELOPMENT AND RESEARCH INSTITUTES   (United States)

^g NEW YORK ACADEMY OF MEDICINE   (United States)

^h JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

ⁱ TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Cost; Cost effectiveness; HCV; IDU; Vaccination; Vaccine

Indexed keywords

HEPATITIS C VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANADA; CHILD; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG USE; ECONOMIC ASPECT; HEPATITIS C; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROPHYLAXIS; RISK ASSESSMENT; VACCINATION;

EID: 13444301075     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.09.023     Document Type: Article

References (72)

1. Remis R, et al., Estimating the number of blood transfusion recipients infected by hepatitis C virus in Canada, 1960-1985 and 1990-1992; Report to Health Canada. June 1998 (http://www.phac-aspc.gc.ca/hcai-iamss/bbp-pts/pub_e. html).
2. H.J. Alter Epidemiology of hepatitis C Hepatology 26 3 Suppl 1 1997 62s 65s
3. G.L. Armstrong The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States Hepatology 31 3 2000 777 782
4. J.B. Wong Estimating future hepatitis C morbidity, mortality, and costs in the United States Am J Public Health 90 10 2000 1562 1569
5. G. Inchauspe, and S. Feinstone Development of a hepatitis C virus vaccine Clin Liver Dis 7 1 2003 243 259 xi
6. X. Forns, J. Bukh, and R.H. Purcell The challenge of developing a vaccine against hepatitis C virus J Hepatol 37 5 2002 684 695
7. D. Naimark Primer on medical decision analysis: Part 5 - Working with Markov processes Med Decis Making 17 2 1997 152 159
8. F.A. Sonnenberg, and J.R. Beck Markov models in medical decision making: a practical guide Med Decis Making 13 4 1993 322 338
9. Krahn M, et al., Estimating the prognosis of Canadians infected with the hepatitis C virus through the blood supply, 1986-1990 first revision of prognostic model incorporating data from the compensation claimant cohort. Toronto: University of Toronto; 2002. p. 133.
10. Krahn M, et al., Estimating the Prognosis of Hepatitis C Patients Infected by Transfusion in Canada between 1986 and 1990; Report to the Joint Committee, Hepatitis C, January 1, 1986-July 1, 1990 Class Actions Settlement, 1999. Available on request from the author.
11. Gold MR, et al. Identifying and valuing outcomes. In: Gold MR, et al., editors. Cost effectiveness in health and medicine, New York: Oxford University Press; 1996.
12. M. Brisson, and W.J. Edmunds Varicella vaccination in England and Wales: cost-utility analysis Arch Dis Child 88 10 2003 862 869
13. S.L. Kulasingam, and E.R. Myers Potential health and economic impact of adding a human papillomavirus vaccine to screening programs J Am Med Soc 290 6 2003 781 789
14. C. Prakash Crucial factors that influence cost-effectiveness of universal hepatitis B immunization in India Int J Technol Assess Health Care 19 1 2003 28 40
15. E.C. Vamvakas, and H.F. Taswell Mortality after blood transfusion Transfus Med Rev 8 4 1994 267 280
16. J.R. Beck, J.P. Kassirer, and S.G. Pauker A convenient approximation of life expectancy (The DEALE) Am J Med 73 1982 883 888
17. S. Dobson, D. Scheifele, and A. Bell Assessment of a universal school-based hepatitis B vaccination program J Am Med Assoc 274 1995 1209 1213
18. M. Krahn, and A.S. Detsky Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis Med Decis Making 13 1 1993 4 20
19. G. Quaglio Compliance with hepatitis B vaccination in 1175 heroin users and risk factors associated with lack of vaccine response Addiction 97 8 2002 985 992
20. F. Lugoboni Hepatitis A virus vaccination among injecting drug users: do we have to change the vaccination schedule? Clin Infect Dis 31 3 2000 847 848
21. F. Lugoboni Immunoresponse to hepatitis B vaccination and adherence campaign among injecting drug users Vaccine 15 9 1997 1014 1016
22. P. Mezzelani High compliance with a hepatitis B virus vaccination program among intravenous drug users J Infect Dis 163 4 1991 923
23. D.C. Des Jarlais Providing hepatitis B vaccination to injection drug users: referral to health clinics vs on-site vaccination at a syringe exchange program Am J Public Health 91 11 2001 1791 1792
24. M. Krahn Costs and cost-effectiveness of a universal, school-based hepatitis B vaccination program Am J Public Health 88 11 1998 1638 1644
25. M.J. Alter The natural history of community-acquired hepatitis C in the United States. The sentinel counties chronic non-A, non-B hepatitis study team [see comments] N Engl J Med 327 27 1992 1899 1905
26. C.L. Miller Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users Hepatology 36 3 2002 737 742
27. R.S. Garfein Prevalence and incidence of hepatitis C virus infection among young adult injection drug users J Acquir Immune Defic Syndr Hum Retrovirol 18 Suppl 1 1998 11 19
28. D.M. Patrick Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection Can Med Assoc J 165 7 2001 889 895
29. S.A. Villano Incidence and risk factors for hepatitis C among injection drug users in Baltimore Maryland J Clin Microbiol 35 12 1997 3274 3277
30. B. Concool, H. Smith, and B. Stimmel Mortality rates of persons entering methadone maintenance: a seven-year study Am J Drug Alcohol Abuse 6 3 1979 345 353
31. A. Eskild Differences in mortality rates and causes of death between HIV positive and HIV negative intravenous drug users Int J Epidemiol 22 2 1993 315 320
32. A.H. Ghodse Deaths of drug addicts in the United Kingdom, 1967-81 Br Med J (Clin Res Ed) 290 6466 1985 425 428
33. A.M. Bargagli Mortality among problem drug users in Rome: an 18-year follow-up study, 1980-97 Addiction 96 10 2001 1455 1463
34. C.A. Perucci Mortality of intravenous drug users in Rome: a cohort study Am J Public Health 81 10 1991 1307 1310
35. J.M. McAnulty Underreporting of AIDS, New South Wales, 1988-1989 Med J Aust 156 7 1992 452 455
36. G.W. Joe, W. Lehman, and D.D. Simpson Addict death rates during a four-year post-treatment follow-up Am J Public Health 72 7 1982 703 709
37. J.J. Goedert Cause-specific mortality associated with HIV and HTLV-II infections among injecting drug users in the USA AIDS 15 10 2001 1295 1302
38. P. Pezzotti Direct comparison of time to AIDS and infectious disease death between HIV seroconverter injection drug users in Italy and the United States: results from the ALIVE and ISS studies. AIDS link to intravenous experiences. Italian seroconversion study J Acquir Immune Defic Syndr Hum Retrovirol 20 3 1999 275 282
39. P. Mezzelani A multicentre study on the causes of death among Italian injecting drug users. AIDS has overtaken overdose as the principal cause of death AIDS Care 10 1 1998 61 67
40. M.W. Tyndall Impact of HIV infection on mortality in a cohort of injection drug users J Acquir Immune Defic Syndr 28 4 2001 351 357
41. H.J. Van Haastrecht Predictors of mortality in the Amsterdam cohort of human immunodeficiency virus (HIV)-positive and HIV-negative drug users Am J Epidemiol 143 4 1996 380 391
42. M. Zaccarelli Impact of HIV infection on non-AIDS mortality among Italian injecting drug users AIDS 8 3 1994 345 350
43. Remis R, Consortium to characterize injection drug users in Canada. Division of HIV/AIDS and STD, Toronto: Laboratory Centre for Disease Control, Health Canada; 1998. p. 73.
44. M.R. Gold Cost-effectiveness in health and medicine 1996 Oxford University Press Inc. New York
45. S.A. Finkler The distinction between cost and charges Ann Intern Med 96 1982 102 109
46. J. Brandeis A nationwide charge comparison of the principal treatments for early stage prostate carcinoma Cancer 89 8 2000 1792 1799
47. M. Mushinski Average charges for hip replacement surgeries: United States, 1997 Stat Bull Metrop Insur Co 80 2 1999 32 40
48. J.A. Hayman A comparison of two methods for estimating the technical costs of external beam radiation therapy Int J Radiat Oncol Biol Phys 47 2 2000 461 467
49. R.P. Myers, J.C. Gregor, and P.J. Marotta The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C Hepatology 31 4 2000 834 839
50. Ontario M.O.H. Schedule of benefits. Physician services under the Health Insurance Act, 1995. Ontario: Ministry of Health.
51. C.A. Chong Health-state utilities and quality of life in hepatitis C patients Am J Gastroenterol 98 3 2003 630 638
52. N. Mittman Utility scores for chronic conditions in a community-dwelling population PharmacoEconomics 15 1999 369 376
53. J. Ware Health-related quality of life in chronic hepatitis C: impact of disease and treatment response. The Interventional Therapy Group J Am Med Assoc 282 3 1999 221 222
54. G.R. Foster, R.D. Goldin, and H.C. Thomas Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis Hepatology 27 1 1998 209 212
55. Siebert U, et al., Health related quality of life in chronic hepatitis C patients: a comparison of different utility assessment methods. Med Decis Making; 2002.
56. A.M. Bayoumi, and D.A. Redelmeier Economic methods for measuring quality of life associated with HIV infection Qual Life Res 8 6 1999 471 480
57. M.L. Essink-Bot, M.E. Stouthard, and G.J. Bonsel Generalizability of valuations on health states collected with the EuroQol questionnaire Health Econ 2 1993 237 246
58. N.P. Hurst Validity of Euroqol - a generic health status instrument - in patients with rheumatoid arthritis Br J Rheumatol 33 1994 655 662
59. A. Laupacis How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations Can Med Assoc J 146 1992 473 481
60. A. Ament Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries Clin Infect Dis 31 2 2000 444 450
61. D. De Graeve, G. Lombaert, and H. Goossens Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium Pharmacoeconomics 17 6 2000 591 601
62. Krahn M, et al. Universal hepatitis A vaccination for adolescents and children in Canada: a cost effectiveness analysis. Toronto: Health Canada; 2001. p. 42.
63. M. Krahn, and A.S. Detsky Universal vaccination against hepatitis B in North America: a cost effectiveness analysis Clin Res 39 1991 379a
64. M. Krahn, R. Guasparini, and M. Sherman Costs and cost effectiveness of a universal, school-based, adolescent hepatitis B vaccination program Am J Public Health 88 1998 1638 1644
65. B.S. Bloom A reappraisal of hepatitis B virus vaccination strategies using cost-effectiveness analysis Ann Intern Med 118 4 1993 298 306
66. T.A. Lieu Cost-effectiveness of a routine varicella vaccination program for US children J Am Med Assoc 271 5 1994 375 381
67. T.A. Lieu Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children J Am Med Assoc 283 11 2000 1460 1468
68. W.J. Edmunds, G.F. Medley, and D.J. Nokes Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective Stat Med 18 23 1999 3263 3282
69. R.B. Savage, M.J. Hussey, and M.B. Hurie A successful approach to immunizing men who have sex with men against hepatitis B Public Health Nurs 17 3 2000 202 206
70. Z.M. Younossi Cost effectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C Hepatology 30 5 1999 1318 1324
71. M.C. Taylor Factors associated with the high cost of liver transplantation in adults Can J Surg 45 6 2002 425 434
72. T.M.C. Group Inter- and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C Hepatology 20 1996 15 20